Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive
Target Price
The average target price of MNKD is 8.1 and suggests 187% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell